Options traders are betting on big moves for Facebook ahead of earnings.» Read More
The Fed said that it would not provide explicit guidance about when rates would go up but then said that rates were unlikely to go up in June.
Matrix Asset Advisors is increasing its stake in McDonald's on the expectation CEO Steve Easterbrook's turnaround plan will succeed.
Trader finds way to make a large amount on Cablevision acquisition speculation.
Morgan Stanley says Apple sales look especially strong—and that in a "bull case," the stock could rise to $195.
Some of the names on the move ahead of the open.
Traders will be watching housing starts to see if the sector will show sign of life on Thursday.
Technician Carter Worth explains why the financials could hold the key to the market rally.
Should you invest in fixed income when corporations are all too eagerly selling new bonds in staggeringly large amounts? Likely not.
Jim Cramer’s telling you to be afraid. Be very afraid.
CNBC Pro used technical and fundamental analysis to find the stocks that are primed to rally the most in the continuation of the bull market.
Headline jobs and employment numbers may look good, but the underlying details of the U.S. economy remain weak, Michael Tyler tells CNBC.
Todd Gordon of TradingAnalysis.com explains why energy stocks could face increased selling pressure.
Jim Cramer was alarmed at what he saw when he looked at transports, especially one group. Time to get out of this group, now.
The "Fast Money" traders give their final trades of the day.
Federal Reserve officials at their April meeting mostly brushed aside the wobbly start the U.S. economy has had in 2015.
Jim Cramer has his eye on one U.S. automaker that has been coming back with a vengeance—and you don't even know it.
Jim Cramer is seeing good things happening with this company, which could spark the housing recovery we have all been waiting for.
Check out the companies making headlines after the bell Wednesday: Williams-Sonoma, Salesforce, NetApp & more.
The cloud computing company—which has been the recent focus of takeover rumors—saw revenue rise 23 percent year over year.
Cheaper biotech drugs are headed to the U.S., but analyst Mike Weinstein thinks J&J can manage through some of the challenges.